AF
MNPR icon

Allworth Financial’s Monopar Therapeutics MNPR Stock Holding History

Allworth Financial’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.08K Buy
111
+11
+11% +$664 ﹤0.01% 3840
2025
Q4 		$6.53K Hold
100
– – ﹤0.01% 3551
2025
Q3 		$8.17K Hold
100
– – ﹤0.01% 3268
2025
Q2 		$3.58K Hold
100
– – ﹤0.01% 3448
2025
Q1 		$4.46K Buy
+100
New +$3.6K ﹤0.01% 2823

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Allworth Financial's MNPR Position: Q1 2026 in Review

Allworth Financial increased its Monopar Therapeutics (MNPR) stake by 11% in Q1 2026, buying an estimated $664 and bringing the position to 111 shares worth $6.08K. The position accounts for ﹤0.01% of the portfolio, ranked #3840.

Allworth Financial first reported a position in MNPR in Q1 2025 and has held it in 5 quarters since. The position peaked at $8.17K in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Allworth Financial held 111 shares of Monopar Therapeutics worth $6.08K as of Q1 2026.
  • Allworth Financial bought 11 Monopar Therapeutics shares in Q1 2026, an estimated $664.
  • Monopar Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #3840 holding.
  • Allworth Financial first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Allworth Financial's Monopar Therapeutics position peaked at $8.17K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.